NCT02599649 2020-01-14Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)M.D. Anderson Cancer CenterPhase 2 Terminated10 enrolled 8 charts
NCT02399917 2019-09-24Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaM.D. Anderson Cancer CenterPhase 2 Terminated36 enrolled 14 charts